Waters Corp to Announce Strong Q1 Earnings on May 5th
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: seekingalpha
Waters Corp's stock rose by 12.71% and reached a 5-day high amid positive earnings expectations.
The company is set to announce its Q1 2023 earnings on May 5th, with a consensus EPS estimate of $2.31, reflecting a 2.7% year-over-year growth. Additionally, revenue is projected to reach $1.2 billion, representing an impressive 81.3% year-over-year increase, which highlights the company's robust performance and may boost investor confidence. Waters has consistently beaten EPS and revenue estimates over the past two years, further enhancing market confidence in its future performance.
This upcoming earnings report is likely to attract significant investor interest, given the company's strong historical performance and optimistic revenue growth outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAT
Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 357.000
Low
350.00
Averages
414.08
High
480.00
Current: 357.000
Low
350.00
Averages
414.08
High
480.00
About WAT
Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Waters Launches Innovative Battery Safety Testing Instrument
- Battery Safety Testing Revolution: Waters Corporation's Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-consuming preparation steps, thereby accelerating testing speed and providing more detailed safety and performance insights.
- Multidimensional Data Capture: This instrument is the only DSC that simultaneously captures thermal, evolved gas, and electrochemical performance data, helping researchers identify thermal runaway and battery failures earlier, enhancing safety in battery development.
- Significant Reduction in Preparation Time: The new capsule design reduces sample preparation time by over 90%, preserving sample integrity while significantly accelerating data generation and optimizing experimental workflows.
- Broad Application Prospects: With a temperature range of -80°C to 600°C, the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, advancing early-stage battery safety research and reducing development risks.
See More
Waters Launches Innovative BioResolve and GTxResolve Columns for Biopharmaceuticals
- Product Launch: Waters Corporation has introduced the BioResolve™ Peptide and GTxResolve™ Lipid Columns, specifically designed to address the challenge of separating structurally similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles, thereby enhancing the safety and efficacy of drug development.
- Market Demand Response: The new columns significantly improve separation efficiency and speed, helping pharmaceutical companies reduce time to market, enhance regulatory confidence, and lower patient safety risks associated with impurities.
- Technical Advantages: The BioResolve and GTxResolve Columns utilize specially designed surface chemistries and superficially porous particles to ensure consistent performance across U(H)PLC and HPLC systems, suitable for all stages from early research to manufacturing.
- Positive Customer Feedback: Researchers from Alembic Pharmaceuticals and Acuitas Therapeutics have expressed high satisfaction with the new products' separation performance, stating that they can meet current and future regulatory requirements while facilitating rapid analysis of complex peptides and lipids.
See More
Waters Corporation Receives FDA Clearance for Next-Gen Blood Culture System
- FDA Clearance: Waters Corporation announced that its BD BACTEC FXI Culture System has received 510(k) clearance from the FDA, marking a significant technological advancement in bloodstream infection diagnostics and is expected to enhance market competitiveness.
- Automation Enhancement: The system features fully automated vial loading, unloading, incubation, and detection alerts, capable of loading up to 60 vials at a time, which is a 50% increase over the leading competing system, thereby significantly improving laboratory efficiency.
- Reduced Detection Time: Clinical study data indicates that the BD BACTEC FXI system reduces the mean time to detection by approximately three hours compared to the previous-generation BD BACTEC FX Blood Culture System, which will accelerate infection diagnosis and improve patient treatment timing.
- Stock Performance: Despite the FDA clearance for the new system, Waters Corporation's shares closed at $371.93 on Tuesday, down 1.65%, indicating a relatively muted market reaction to the news.
See More
FDA Approves BD BACTEC FXI Culture System for U.S. Market
- Reduced Detection Time: The BD BACTEC FXI Culture System achieves a mean time to detection that is approximately three hours faster (about 15% reduction) than its predecessor, significantly enhancing early pathogen identification and timely antimicrobial therapy, which is crucial for reducing mortality rates.
- Enhanced Automation: This system features an industry-leading automated loading capacity of up to 960 vials, which maximizes laboratory efficiency by minimizing manual intervention and increasing staff walk-away time, thereby streamlining workflow in high-throughput microbiology labs.
- International Certification Expansion: The BD BACTEC FXI Culture System has received CE marking and licensing from Japan's PMDA, indicating its availability in European and Japanese markets, which strengthens its competitive position globally.
- Significant Clinical Impact: Rapid laboratory results are critical for timely clinical decisions, especially in acute care settings, where each hour of delayed treatment can increase mortality by 3.6% to 9.9%, underscoring the system's importance in modern microbiology laboratories.
See More
Market Capitalization Comparison: Steel Dynamics vs. Waters Corp.
- Market Cap Comparison: Steel Dynamics Inc. (STLD) has a market capitalization of $37.72 billion, compared to Waters Corp. (WAT) at $37.13 billion, highlighting the relative value differences that can influence investor decisions and capital flows.
- Investor Misconception: Many novice investors mistakenly compare stock prices to gauge company value, but market capitalization provides a more accurate assessment of company size, enabling smarter investment choices.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs may invest in these stocks, thereby influencing their liquidity and market performance.
- Stock Performance: At Tuesday's close, STLD shares rose approximately 3.8%, while WAT shares fell about 1.6%, reflecting differing market expectations for the future performance of the two companies.
See More
Waters Launches New Cyclic IMS P20 Mass Spectrometer
- Technological Innovation: The launch of the Cyclic IMS P20 Mass Spectrometer by Waters Corporation features over a 10-fold increase in MS/MS sensitivity, significantly enhancing the analysis of low-abundance molecules, thereby accelerating research into disease mechanisms and drug development.
- Integrated Functionality: This instrument combines MALDI and DESI imaging sources, providing a more comprehensive molecular view that helps researchers observe small molecules, lipids, peptides, and proteins more clearly in samples, facilitating biomarker identification.
- Market Launch: The Cyclic IMS P20 Mass Spectrometer is expected to be available globally in September 2026, marking Waters' ongoing innovation in the life sciences sector and enabling scientists to discover and develop new therapies more rapidly.
- Growing Market Demand: As researchers pursue larger and more heterogeneous therapeutic targets, the high sensitivity and structural resolution of this instrument meet the needs of modern analytical workflows, further solidifying Waters' leadership position in the analytical technology market.
See More
Waters Launches Innovative Battery Safety Testing Instrument
- Battery Safety Testing Revolution: Waters Corporation's Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-consuming preparation steps, thereby accelerating testing speed and providing more detailed safety and performance insights.
- Multidimensional Data Capture: This instrument is the only DSC that simultaneously captures thermal, evolved gas, and electrochemical performance data, helping researchers identify thermal runaway and battery failures earlier, enhancing safety in battery development.
- Significant Reduction in Preparation Time: The new capsule design reduces sample preparation time by over 90%, preserving sample integrity while significantly accelerating data generation and optimizing experimental workflows.
- Broad Application Prospects: With a temperature range of -80°C to 600°C, the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, advancing early-stage battery safety research and reducing development risks.
See More
Waters Launches Innovative BioResolve and GTxResolve Columns for Biopharmaceuticals
- Product Launch: Waters Corporation has introduced the BioResolve™ Peptide and GTxResolve™ Lipid Columns, specifically designed to address the challenge of separating structurally similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles, thereby enhancing the safety and efficacy of drug development.
- Market Demand Response: The new columns significantly improve separation efficiency and speed, helping pharmaceutical companies reduce time to market, enhance regulatory confidence, and lower patient safety risks associated with impurities.
- Technical Advantages: The BioResolve and GTxResolve Columns utilize specially designed surface chemistries and superficially porous particles to ensure consistent performance across U(H)PLC and HPLC systems, suitable for all stages from early research to manufacturing.
- Positive Customer Feedback: Researchers from Alembic Pharmaceuticals and Acuitas Therapeutics have expressed high satisfaction with the new products' separation performance, stating that they can meet current and future regulatory requirements while facilitating rapid analysis of complex peptides and lipids.
See More
Waters Corporation Receives FDA Clearance for Next-Gen Blood Culture System
- FDA Clearance: Waters Corporation announced that its BD BACTEC FXI Culture System has received 510(k) clearance from the FDA, marking a significant technological advancement in bloodstream infection diagnostics and is expected to enhance market competitiveness.
- Automation Enhancement: The system features fully automated vial loading, unloading, incubation, and detection alerts, capable of loading up to 60 vials at a time, which is a 50% increase over the leading competing system, thereby significantly improving laboratory efficiency.
- Reduced Detection Time: Clinical study data indicates that the BD BACTEC FXI system reduces the mean time to detection by approximately three hours compared to the previous-generation BD BACTEC FX Blood Culture System, which will accelerate infection diagnosis and improve patient treatment timing.
- Stock Performance: Despite the FDA clearance for the new system, Waters Corporation's shares closed at $371.93 on Tuesday, down 1.65%, indicating a relatively muted market reaction to the news.
See More
FDA Approves BD BACTEC FXI Culture System for U.S. Market
- Reduced Detection Time: The BD BACTEC FXI Culture System achieves a mean time to detection that is approximately three hours faster (about 15% reduction) than its predecessor, significantly enhancing early pathogen identification and timely antimicrobial therapy, which is crucial for reducing mortality rates.
- Enhanced Automation: This system features an industry-leading automated loading capacity of up to 960 vials, which maximizes laboratory efficiency by minimizing manual intervention and increasing staff walk-away time, thereby streamlining workflow in high-throughput microbiology labs.
- International Certification Expansion: The BD BACTEC FXI Culture System has received CE marking and licensing from Japan's PMDA, indicating its availability in European and Japanese markets, which strengthens its competitive position globally.
- Significant Clinical Impact: Rapid laboratory results are critical for timely clinical decisions, especially in acute care settings, where each hour of delayed treatment can increase mortality by 3.6% to 9.9%, underscoring the system's importance in modern microbiology laboratories.
See More
Market Capitalization Comparison: Steel Dynamics vs. Waters Corp.
- Market Cap Comparison: Steel Dynamics Inc. (STLD) has a market capitalization of $37.72 billion, compared to Waters Corp. (WAT) at $37.13 billion, highlighting the relative value differences that can influence investor decisions and capital flows.
- Investor Misconception: Many novice investors mistakenly compare stock prices to gauge company value, but market capitalization provides a more accurate assessment of company size, enabling smarter investment choices.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs may invest in these stocks, thereby influencing their liquidity and market performance.
- Stock Performance: At Tuesday's close, STLD shares rose approximately 3.8%, while WAT shares fell about 1.6%, reflecting differing market expectations for the future performance of the two companies.
See More
Waters Launches New Cyclic IMS P20 Mass Spectrometer
- Technological Innovation: The launch of the Cyclic IMS P20 Mass Spectrometer by Waters Corporation features over a 10-fold increase in MS/MS sensitivity, significantly enhancing the analysis of low-abundance molecules, thereby accelerating research into disease mechanisms and drug development.
- Integrated Functionality: This instrument combines MALDI and DESI imaging sources, providing a more comprehensive molecular view that helps researchers observe small molecules, lipids, peptides, and proteins more clearly in samples, facilitating biomarker identification.
- Market Launch: The Cyclic IMS P20 Mass Spectrometer is expected to be available globally in September 2026, marking Waters' ongoing innovation in the life sciences sector and enabling scientists to discover and develop new therapies more rapidly.
- Growing Market Demand: As researchers pursue larger and more heterogeneous therapeutic targets, the high sensitivity and structural resolution of this instrument meet the needs of modern analytical workflows, further solidifying Waters' leadership position in the analytical technology market.
See More
